INTERNATIONAL CONFERENCE ON CELL SCIENCE AND REGENERATIVE MEDICINE

Haojie Jin

Shanghai Cancer Institute, China

Drug-drug synthetic lethality to combat liver cancer: From bench to bedside

Abstract: Recently, drug–drug synthetic lethality was developed to counter intrinsic drug resistance that often results from feedback-mediated activation of the same or a parallel signalling pathway upon drug treatment. The high-throughput technologies of CRISPR-Cas9-mediated gene knockout have greatly facilitated unbiased discovery of such drug–drug synthetic lethality. Here, we will discuss two examples of drug–drug synthetic lethality, which have been translated from 'bench to bed', highlighting the power of high-throughput screening in guiding the design of clinical combination therapies.

ISBN: 978-1-0685851-4-2